IDEAYA Biosciences/$IDYA
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About IDEAYA Biosciences
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275/GSK959 (Werner Helicase), IDE161 (PARG), and IDE705/GSK101 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.
Ticker
$IDYA
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
131
ISIN
US45166A1025
Website
IDYA Metrics
BasicAdvanced
$2B
-
-$3.61
0.25
-
Price and volume
Market cap
$2B
Beta
0.25
52-week high
$44.42
52-week low
$13.45
Average daily volume
1.2M
Financial strength
Current ratio
13.922
Quick ratio
13.62
Long term debt to equity
2.506
Total debt to equity
2.536
Profitability
EBITDA (TTM)
-357.976
Gross margin (TTM)
-4,510.77%
Net profit margin (TTM)
-4,386.90%
Operating margin (TTM)
-5,147.81%
Revenue per employee (TTM)
$50,000
Management effectiveness
Return on assets (TTM)
-21.84%
Return on equity (TTM)
-31.34%
Valuation
Price to revenue (TTM)
276.827
Price to book
1.95
Price to tangible book (TTM)
1.95
Price to free cash flow (TTM)
-7.231
Free cash flow yield (TTM)
-13.83%
Free cash flow per share (TTM)
-315.30%
Growth
Revenue change (TTM)
-54.85%
Earnings per share change (TTM)
79.98%
3-year revenue growth (CAGR)
-39.78%
3-year earnings per share growth (CAGR)
34.61%
What the Analysts think about IDYA
Analyst ratings (Buy, Hold, Sell) for IDEAYA Biosciences stock.
Bulls say / Bears say
UBS initiated coverage of IDEAYA Biosciences with a Buy rating and a $50 price target, highlighting the transformative potential of its multi-billion dollar uveal melanoma therapy. (nasdaq.com)
IDEAYA reported having approximately $1.1 billion in cash, cash equivalents, and marketable securities as of December 31, 2024, providing a cash runway into at least 2028. (wwlp.com)
The company announced a successful FDA Type D meeting regarding the Phase 3 registrational trial design for darovasertib as neoadjuvant therapy for primary uveal melanoma, with plans to initiate the trial in the first half of 2025. (stocktitan.net)
IDEAYA Biosciences' stock reached a 52-week low of $21.02 on February 12, 2025, reflecting a significant downturn and a 54% decrease over the past year. (investing.com)
Research and development expenses for the three months ended December 31, 2024, totaled $140.2 million, a substantial increase from $38.8 million in the same period of 2023, primarily due to a $75.0 million upfront payment under a license agreement. (wwlp.com)
Analysts have revised their earnings downwards for the upcoming period and anticipate a sales decline in the current year, indicating potential financial challenges ahead. (investing.com)
Data summarised monthly by Lightyear AI. Last updated on 9 Jul 2025.
IDYA Financial Performance
Revenues and expenses
IDYA Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for IDEAYA Biosciences stock?
IDEAYA Biosciences (IDYA) has a market cap of $2B as of July 11, 2025.
What is the P/E ratio for IDEAYA Biosciences stock?
The price to earnings (P/E) ratio for IDEAYA Biosciences (IDYA) stock is 0 as of July 11, 2025.
Does IDEAYA Biosciences stock pay dividends?
No, IDEAYA Biosciences (IDYA) stock does not pay dividends to its shareholders as of July 11, 2025.
When is the next IDEAYA Biosciences dividend payment date?
IDEAYA Biosciences (IDYA) stock does not pay dividends to its shareholders.
What is the beta indicator for IDEAYA Biosciences?
IDEAYA Biosciences (IDYA) has a beta rating of 0.25. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.